Finasteride vs dutasteride for hair loss is a choice between the FDA-labeled option and an off-label drug that showed more regrowth over 24 weeks. Finasteride is approved for male androgenetic alopecia. Dutasteride is approved for benign prostatic hyperplasia, so its use for hair loss is off-label. A head-to-head meta-analysis favored dutasteride for hair count and found no statistically significant difference in three sexual-function outcomes. A prescriber weighs those findings against your response, tolerability, and goals.1,2,3
Comparison Table for Finasteride vs Dutasteride
The regulatory difference is clear. The comparative efficacy evidence points in another direction.
| Drug | FDA-approved indication | Typical regulatory status for hair loss | What the best head-to-head evidence found |
|---|---|---|---|
| Finasteride | Male pattern hair loss, also called androgenetic alopecia, in men | FDA-approved for hair loss | Produced less improvement in total hair count than dutasteride over 24 weeks. The analysis found no statistically significant difference between the drugs in altered libido, erectile dysfunction, or ejaculation disorders.1,3 |
| Dutasteride | Symptomatic benign prostatic hyperplasia in men with an enlarged prostate | Off-label for hair loss in the United States | Produced greater improvement in total hair count. Investigator ratings, photographic assessments, and participant self-assessments also favored dutasteride.2,3 |
The table does not identify one drug as the right choice for every man. Finasteride has the labeled hair-loss indication. Dutasteride has the stronger 24-week efficacy result in the cited comparison, but its hair-loss use remains off-label in the United States.
Your prescriber has to weigh both facts. Individual response and tolerability can then change the decision over time.
Regulatory Status for Hair Loss
Finasteride has a U.S. Food and Drug Administration (FDA) indication for male pattern hair loss in men. The Propecia prescribing information states that indication directly.1
The Avodart prescribing information lists dutasteride for symptomatic benign prostatic hyperplasia in men with an enlarged prostate.2 It does not include hair loss as an approved indication. A U.S. prescription of dutasteride for hair loss is therefore off-label.
Off-label describes a use outside the indication listed in the FDA-approved prescribing information. It does not erase the clinical evidence, but it changes the conversation you need to have with your prescriber. You should know which drug has the hair-loss indication before comparing trial results.
This distinction also keeps separate clinical questions in their proper setting. If you are comparing treatment for urinary symptoms or an enlarged prostate, you need a urology-specific evaluation. This page addresses male hair loss.
If you are still determining whether your changes match androgenetic alopecia, start with the first signs of hair loss and the broader male pattern baldness guide.
The Shared DHT Pathway
Finasteride and dutasteride are 5-alpha-reductase inhibitors. Both reduce the conversion of testosterone to dihydrotestosterone (DHT), which places them in the same medication class.3,4
That shared mechanism explains why the two drugs can be compared directly in men with androgenetic alopecia. It does not make their regulatory status or clinical evidence interchangeable.
The cited sources do not provide the isoenzyme details needed for a narrower mechanism comparison. Those details should not be inferred from the hair-count results. The useful point is simpler: both drugs reduce DHT, and the head-to-head trials measured whether one produced greater hair improvement.
The DHT blocker overview explains the broader treatment category. If you are comparing a DHT-targeting medication with minoxidil, use the separate finasteride vs minoxidil comparison rather than applying this drug-to-drug evidence to a different mechanism.
Head-to-Head Hair Regrowth Evidence
The best cited head-to-head analysis favored dutasteride over finasteride after 24 weeks. The 2019 systematic review and meta-analysis included three randomized controlled trials with 576 men. Of those participants, 290 received dutasteride and 286 received finasteride.3
The pooled total hair-count result showed a mean difference of 28.57 hairs favoring dutasteride, with a P value below 0.00001.3 Investigator assessments of the vertex and frontal views also favored dutasteride. Photographic-panel assessments and participant self-assessments pointed in the same direction.3
A mean difference is a comparison between study groups. It does not predict the exact number of hairs you would gain or tell you how visible the change would be. Your response may differ from the pooled average.
The study window also sets a firm limit on the conclusion. The analysis establishes a comparative advantage for dutasteride at 24 weeks. It does not establish how the two drugs compare over several years.
The practical conclusion is narrow. Dutasteride produced greater regrowth in the available short-term randomized evidence, while finasteride remains the medication with the FDA-approved male hair-loss indication.
Sexual Side Effects in Context
The head-to-head and placebo-controlled analyses answer different safety questions. Reading them together prevents the class-level finding from being mistaken for a difference between the two drugs.
In the three-trial comparison, researchers found no statistically significant difference between dutasteride and finasteride in altered libido, erectile dysfunction, or ejaculation disorders.3 The reported P values were 0.54 for altered libido, 0.07 for erectile dysfunction, and 0.58 for ejaculation disorders.3
A lack of statistical difference does not prove that the risks are identical. It means the analysis did not detect a reliable difference between the two treatment groups for those outcomes.
A separate meta-analysis examined 15 randomized, double-blinded, placebo-controlled trials with 4,495 subjects. Finasteride and dutasteride were pooled as one class. Compared with placebo, 5-alpha-reductase inhibitors had an odds ratio of 1.57 for sexual dysfunction, with a 95% confidence interval from 1.19 to 2.08.4
That figure compares the drug class with placebo. It does not show that dutasteride carries more sexual risk than finasteride. The direct comparison found no statistically significant difference between the two drugs in the three measured sexual-function categories.3
Neither analysis establishes whether a sexual side effect would be permanent or reversible. If you notice a change in libido, erections, or ejaculation during treatment, your prescriber should assess the symptom and decide whether the plan needs to change.
Factors a Prescriber Weighs
A prescriber can base the finasteride vs dutasteride decision on three points supported by this comparison:
- Regulatory status. Finasteride has an FDA-approved indication for male androgenetic alopecia. Dutasteride does not.1,2
- Comparative efficacy. The 24-week meta-analysis found greater hair-count improvement with dutasteride.3
- Response and tolerability. Your physician can reassess the plan based on the changes you report and any side effects you experience.
The evidence does not support choosing dutasteride on hair-count data alone. Its off-label status remains part of the prescribing decision, and the cited comparative trials stop at 24 weeks.
The answer can also change after treatment begins. A poor response, a new symptom, or a tolerability problem gives your physician a reason to revisit the plan. Longer-term comparative research could also change how the two medications are weighed.
This comparison is not a self-selection guide. It also does not establish which medication is cheaper because the cited sources contain no price data. Current cost requires a separate discussion using your exact prescription and pharmacy.
The Opt Take on Finasteride vs Dutasteride
At Opt Health, a physician reviews your existing conditions, current medications, symptoms, and goals before setting a treatment plan. If a prescription becomes part of that plan, the same physician can reassess your response and tolerability instead of treating the first choice as permanent.
Hair count is one data point. Regulatory status, side effects, your broader health, and how you respond form the pattern that guides the next decision. The plan should change when the pattern changes.
Bring this finasteride vs dutasteride comparison to your physician and ask how the FDA labels, 24-week evidence, and your tolerance should shape a monitored plan.
Get started: Begin with Opt Health, where a physician reads your labs, builds your plan, and adjusts it over the loop.
Frequently Asked Questions
Switching can be worth discussing if your response or tolerability gives your prescriber a reason to reconsider the plan. The head-to-head meta-analysis found greater hair-count improvement with dutasteride over 24 weeks.3
That finding does not make a switch automatic. Dutasteride remains off-label for hair loss in the United States, and the cited analysis does not establish comparative outcomes beyond 24 weeks.2,3 Your prescriber should weigh the regulatory difference, your treatment response, and any side effects before changing a prescription.
The cited evidence does not establish that dutasteride causes permanent erectile dysfunction. The head-to-head analysis measured erectile dysfunction during the study period and found no statistically significant difference between dutasteride and finasteride.3
The larger class-level meta-analysis found higher pooled odds of sexual dysfunction with 5-alpha-reductase inhibitors than with placebo.4 It did not establish permanence or reversibility. If erectile dysfunction develops during treatment, your prescriber should evaluate it rather than assume its duration or cause.
The cited sources do not use “feminizing” as a clinical outcome, and they do not report a finding that supports that premise. The term is too broad to describe a specific symptom.
The comparative analysis assessed altered libido, erectile dysfunction, and ejaculation disorders. It found no statistically significant difference between dutasteride and finasteride in those categories.3 If you have a specific concern about a physical or sexual change, name the symptom when you speak with your prescriber.
The available evidence supports a measured discussion about sexual side effects. In the direct comparison, dutasteride did not differ statistically from finasteride in altered libido, erectile dysfunction, or ejaculation disorders.3
Across both drugs pooled as a class, the placebo-controlled meta-analysis reported an odds ratio of 1.57 for sexual dysfunction.4 That number does not provide your individual probability, and it does not isolate dutasteride. Your medical history, symptoms, and response need to be reviewed by your prescriber.
The cited head-to-head evidence does not establish that one drug is safer for the three measured sexual-function outcomes. No statistically significant difference appeared for altered libido, erectile dysfunction, or ejaculation disorders.3
Finasteride has the clearer regulatory position for hair loss because its FDA-approved indication covers male androgenetic alopecia.1 Dutasteride’s hair-loss use is off-label.2 Regulatory status and safety are different questions, so your prescriber should consider both when choosing a treatment.
The cited evidence does not establish a maximum number of years for dutasteride use in hair-loss treatment. The comparative meta-analysis followed treatment for 24 weeks, which cannot answer a multi-year duration question.3
Dutasteride also lacks an FDA-approved hair-loss indication, so its label does not provide a labeled hair-loss duration.2 Ongoing use requires physician monitoring of your response, side effects, current medications, and reasons for continuing treatment.
References
- Organon LLC. PROPECIA (finasteride) tablets: full prescribing information. U.S. Food and Drug Administration. Revised July 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020788s030lbl.pdf
- GlaxoSmithKline. AVODART (dutasteride) soft gelatin capsules: full prescribing information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021319s032lbl.pdf
- Zhou Z, Song S, Gao Z, Wu J, Ma J, Cui Y. The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis. Clin Interv Aging. 2019;14:399-406. https://pubmed.ncbi.nlm.nih.gov/30863034/
- Lee S, Lee YB, Choe SJ, Lee WS. Adverse sexual effects of treatment with finasteride or dutasteride for male androgenetic alopecia: a systematic review and meta-analysis. Acta Derm Venereol. 2019;99(1):12-17. https://pubmed.ncbi.nlm.nih.gov/30206635/
This content is for informational purposes and does not replace evaluation, diagnosis, or treatment by a qualified medical professional.
This article is part of our guide to hair loss. See how Opt Health treats hair loss in men.
Start Today
Your health, your terms. Discover how personalized care can transform not just the way you feel, but how you live.